Cholinergic Crisis

Cholinergic crisis is a life-threatening toxidrome caused by excessive acetylcholine activity at muscarinic and nicotinic receptors, resulting from acetylcholinesterase (AChE) inhibition or direct cholinergic agonism ^[8]C4. The syndrome is characterized by a predictable constellation of peripheral parasympathomimetic effects and central nervous system excitation that can progress to status epilepticus, respiratory failure, and death ^[2]D5[5]D5.

Also Called / Synonyms

• Cholinergic toxidrome
• SLUDGE syndrome (salivation, lacrimation, urination, defecation, gastrointestinal upset, emesis) ^[2]D5
• Cholinergic storm
• Organophosphate (OP) poisoning syndrome (when due to OPs)
• Nerve agent poisoning (when due to chemical warfare agents)

Classification by Etiology

The cholinergic crisis arises from four principal mechanisms, each with distinct clinical implications:

Plant toxins (e.g., Lycoris radiata containing galanthamine) and certain venoms can also precipitate a cholinergic crisis through the same mechanisms ^[6]C4.

Phases and Spectrum

• Acute cholinergic crisis: Develops within minutes to hours of exposure; dominated by muscarinic (SLUDGE, bronchospasm, bradycardia) and nicotinic (fasciculations, weakness, paralysis) signs, with central effects (seizures, coma) ^[5]D5[10]D5.
• Intermediate syndrome: A distinct entity of muscle weakness appearing 24-96 hours after OP poisoning, covered in the complications section.
• Organophosphate-induced delayed neuropathy (OPIDN): A distal axonopathy occurring weeks after acute crisis, associated with chlorpyrifos and other specific OPs ^[18]B2b.

Clinical Significance

Cholinergic crisis is a medical emergency with high mortality if untreated. In MuSK-antibody positive myasthenia gravis, even therapeutic doses of acetylcholinesterase inhibitors can precipitate a crisis, with 7.3% of patients in one large cohort suffering this complication ^[12]B3b. Prompt recognition of the toxidrome and administration of antidotes (atropine, oximes) are life-saving.

The mechanisms that drive the dangerous differential, including the nuances of aging, reactivation, and central nervous system penetration, are explored in the next section.

Pearl: Etiologic classification (organophosphate, carbamate, iatrogenic, direct agonist) guides prognosis and antidote choice, with irreversible OPs requiring oxime therapy before aging occurs.

With the classification of cholinergic crisis established, the clinician must now hold in parallel the competing life-threatening mechanisms that produce the same core clinical picture, excessive muscarinic, nicotinic, and CNS signs, via distinct physiologic routes. The differential is not merely a list of poisonings; it encompasses autoimmune, neurodegenerative, and iatrogenic conditions that mimic the toxidrome or follow its acute phase. Mistaking one for another can lead to fatal delays in antidote administration or, conversely, to inappropriate therapy that worsens outcome.

Comparison Table: Life-Threatening Mimics of Cholinergic Crisis

When to Suspect Each Alternative

• Acute OP poisoning: Suspect in any patient with acute SLUDGE syndrome, fasciculations, and depressed mental status, especially with a history of agricultural or intentional ingestion ^[27]D5.
• Carbamate poisoning: Consider when cholinergic crisis is unusually brief (resolves within hours) or when the patient brings a container labeled as a carbamate (e.g., aldicarb) ^[34]C4.
• Nerve agent exposure: Suspect in mass casualty events, military settings, or terrorist attacks; the hallmark is rapid progression to seizures and apnea within minutes ^[22]D5.
• Myasthenic crisis (MuSK‑MG): Suspect when weakness is purely neuromuscular (no muscarinic signs, no fasciculations) and symptoms fluctuate; ask about prior ptosis, diplopia, or dysphagia ^[4]D5.
• Intermediate syndrome: Suspect in any patient who has recovered from an acute OP cholinergic crisis but then develops new proximal muscle weakness and respiratory difficulty 2-4 days later ^[31]D5.

Must‑Not‑Miss Differentials

• Botulism : Presents with descending flaccid paralysis, bulbar palsy, and dilated pupils (anticholinergic, not cholinergic) - key differentiator is absence of muscarinic signs and presence of clear sensorium. Rule out with stool or serum botulinum toxin assay.
• Lambert‑Eaton myasthenic syndrome: Proximal weakness that improves with exercise; autonomic symptoms (dry mouth, constipation) but no cholinergic excess. RNS shows increment at high‑rate stimulation ^[32]C4.
• Organophosphate‑induced delayed neuropathy (OPIDN): Occurs weeks after acute OP exposure, producing distal axonopathy with foot drop, gait ataxia, and sensory loss - not a cholinergic crisis, but catastrophic if missed because it is irreversible ^{[18]B2b[19]D5}.

When to Reconsider the Diagnosis

• Symptoms progressing beyond 48 h without a clear source of OP exposure → reconsider myasthenic crisis or inflammatory neuropathy.
• Cholinergic crisis that does not improve with atropine and oxime → consider carbamate poisoning (oximes may be unnecessary) or nerve agent with refractory seizures ^[28]D5.
• Development of proximal weakness 24-96 h after initial recovery → suspect IMS, not a relapse of cholinergic crisis ^[31]D5.
• New foot drop, ataxia, or distal paresthesias weeks after exposure → evaluate for OPIDN; nerve conduction studies show axonal degeneration, motor > sensory ^[18]B2b.

Pearl: Myasthenic crisis (MuSK‑MG) is the one mimic in which cholinesterase inhibitors are contraindicated, edrophonium testing can worsen weakness, and pyridostigmine may precipitate a paradoxical cholinergic crisis ^[4]D5.

From the mechanisms of acetylcholinesterase inhibition, the clinical burden of cholinergic crisis arises from two distinct etiologic streams: acute poisoning by organophosphates (OPs) and carbamates, and iatrogenic overdose of reversible cholinesterase inhibitors used for myasthenia gravis , underactive bladder (distigmine), or dementia (donepezil). The global incidence of acute OP poisoning is immense, thousands of deaths occur every year, concentrated in developing countries following deliberate self-ingestion of pesticides such as methyl parathion, dichlorvos, dimethoate, and chlorpyrifos ^[27]D5. In the veterinary literature, anticholinesterase intoxication in dogs is predominantly from OP and carbamate compounds, with 72% of cases presenting as acute cholinergic crisis (ACC) alone and 22% progressing to intermediate syndrome (IMS) ^[35]D5. The clinical relevance of these numbers is that IMS typically declares itself 7-96 hours after the initial crisis and is a major contributor to respiratory failure ^[35]D5.

Iatrogenic Etiology: Distigmine and Reversible Inhibitors

Distigmine, a reversible cholinesterase inhibitor used for underactive bladder, carries a well-documented risk of cholinergic crisis. In a retrospective cohort of 93 patients, 24% experienced adverse drug reactions (ADRs) warranting discontinuation, with diarrhea (16 cases), impaired consciousness, respiratory depression, miosis, and bradycardia being the most common ^[37]B2b. The risk is dose‑ and age‑dependent: a dose >0.1 mg/kg/d (odds ratio 3.19, 95% CI 1.24-8.19) and age >85 years (OR 3.04, 95% CI 1.18-7.82) were independently associated with a serum cholinesterase (sChE) level ≤129 U/L, the cutoff identified by ROC analysis for predicting ADRs (AUC 0.8, 95% CI 0.7-0.9; sensitivity 0.86, specificity 0.68) ^[37]B2b. Although not significant in multivariate modeling, the percentage of ADRs increased with advancing chronic kidney disease (CKD) stage: from 18% in stage 1 to 40% in stage 4, suggesting that renal impairment may potentiate distigmine accumulation ^[37]B2b.

Risk Factor Summary

Among patients with acute OP poisoning, pneumonia develops in 20-50% of cases, predominantly caused by Gram‑negative bacilli (especially Pseudomonas aeruginosa ), and should be anticipated in the ICU setting ^[36]B2b.

Pearl: In any patient on a cholinesterase inhibitor (e.g., distigmine) who presents with new diarrhea, altered consciousness, or respiratory depression, measure a serum cholinesterase level; a value ≤129 U/L identifies those at high risk of progressing to frank cholinergic crisis and warrants immediate dose reduction or drug discontinuation ^[37]B2b.

The risk factors and epidemiology outlined above set the stage for the clinical encounter: a patient with a history of pesticide exposure, ingestion, or chemical warfare agent contact who presents with a rapidly evolving toxidrome. Recognition hinges on the triad of muscarinic, nicotinic, and central nervous system (CNS) signs, which together define the cholinergic crisis.

Onset and Timeline

Symptoms begin within minutes to hours of exposure, depending on the route and agent. For organophosphates, the acute cholinergic crisis peaks in the first 24 hours ^[2]D5. Carbamates, being reversible inhibitors, produce a shorter-lived syndrome that often resolves within 24 hours ^[44]D5. However, exceptions exist: delayed onset up to 8 hours after ingestion of Lycoris radiata (containing galanthamine, a carbamate) has been reported, with symptoms persisting for days ^[6]C4. The intermediate syndrome (IMS) follows 24-96 hours after the acute crisis and manifests as proximal muscle weakness, neck flexor weakness, and respiratory compromise ^[29]D5[35]D5.

The Cholinergic Toxidrome

The clinical picture is driven by acetylcholine accumulation at muscarinic and nicotinic receptors, plus CNS effects. The mnemonic SLUDGE (Salivation, Lacrimation, Urination, Defecation, Gastrointestinal upset, Emesis) captures muscarinic excess, but key nicotinic signs, fasciculations, weakness, and autonomic instability, are equally critical. The table below outlines the operating characteristics of each finding.

Neurological Examination Findings

Examination must be systematic and rapid. Assess for fasciculations, visible, fine, rapid twitching of facial, limb, and trunk muscles, which reflect nicotinic overactivity at the neuromuscular junction ^[46]C4. Multiple motor responses to a single nerve stimulus on nerve conduction studies is a characteristic electrophysiological pattern of cholinergic crisis, caused by persistent acetylcholine in the synaptic cleft ^[46]C4.

Proximal muscle strength (neck flexion, shoulder abduction, hip flexion) should be tested: weakness that begins 24-96 hours after the acute crisis heralds IMS ^[29]D5. Cranial nerve examination may reveal bilateral vocal cord paralysis presenting as dysphonia or post-extubation stridor ^[41]C4. Laryngeal electromyography can confirm vagus nerve involvement ^[41]C4. Dysphagia can be assessed with the FEES-Tensilon Test, which distinguishes myasthenic from cholinergic crisis by observing improvement after edrophonium (Tensilon) administration ^[42]C4.

Red Flags and Atypical Presentations

• Respiratory failure: FVC < 15 mL/kg or declining vital capacity signals impending neuromuscular respiratory failure; consider early intubation ^[29]D5.
• Hypotension and bradycardia: Require aggressive fluid resuscitation and atropine. An erythrocyte acetylcholinesterase (EAChE) activity < 23.5 µmol/mL/h at admission correlates with coma, respiratory failure, and death ^[45]B2b.
• Seizures: Prolonged status epilepticus despite benzodiazepines is associated with later development of epilepsy ^[10]D5.

Atypical presentations include cortical blindness (visual evoked potential and MRI confirm) and delayed peripheral neuropathy (e.g., bilateral peroneal nerve palsy) days to weeks after carbamate poisoning ^[40]C4. Isolated bilateral vocal cord paralysis may be the only sign of IMS after extubation ^[41]C4.

Pearl: The absence of miosis or bradycardia does not rule out cholinergic crisis, especially in the setting of co-ingestants (e.g., anticholinergics) or early CNS-predominant forms. Instead, look for fasciculations and proximal muscle weakness as the most reliable nicotinic signs; if present, treat empirically while awaiting confirmatory testing.

From the clinical presentation of SLUDGE (salivation, lacrimation, urination, defecation, gastrointestinal upset, emesis) plus nicotinic signs (fasciculations, weakness, tachycardia, hypertension ) and central nervous system effects (seizures, coma), the clinician must immediately pivot to the diagnostic sieve: enumerate the can't-miss differentials in priority order, apply validated rule-out instruments, and confirm the diagnosis to guide specific therapy.

The Worst-First Differential

The cholinergic toxidrome is not pathognomonic for organophosphate (OP) poisoning. The following must be systematically excluded:

• Carbamate poisoning - identical muscarinic and nicotinic signs but acetylcholinesterase (AChE) inhibition is reversible; oximes are not indicated and may be harmful. Differentiate by history (carbaryl, aldicarb) and, if available, by measuring reactivatability of AChE.
• Nerve agent exposure (sarin, VX, tabun) - more rapid onset, higher seizure burden, and often associated with chemical warfare context. Clinical features indistinguishable from OP pesticides; requires same initial therapy.
• Myasthenia gravis cholinergic crisis - Overmedication with acetylcholinesterase inhibitors (AChEIs) in AChR-antibody MG can produce a cholinergic crisis. However, in MuSK-antibody MG, AChEIs frequently cause cholinergic side effects without benefit: among 165 MuSK-MG patients, 76.9% reported at least one side effect and 7.3% (12 patients) suffered a cholinergic crisis ^[12]B3b. AChEIs should be avoided in MuSK-MG ^[12]B3b. Distinguish by history of MG, rapid onset after AChEI dose, and lack of SLUDGE.
• Cholinergic alkaloid poisoning - e.g., Lycoris radiata (contains galanthamine, a carbamate) can cause delayed cholinergic crisis with miosis, hypersalivation, increased airway secretions, vomiting, diarrhea, and myoclonus, and low serum butyrylcholinesterase (BChE) levels ^[6]C4. Carpronium chloride (topical alopecia solution) has a chemical structure similar to acetylcholine, and ingestion produces cholinergic crisis with excess salivation, sweating, and hot flush ^[8]C4.
• Pilocarpine overdose - direct muscarinic agonist, no nicotinic signs, responds to atropine only.

Bedside Diagnosis: The Toxidrome

No single bedside test replaces pattern recognition. The cholinergic crisis is diagnosed by the simultaneous presence of:

• Muscarinic signs (miosis, bradycardia, bronchorrhea, wheezing, excessive secretions, urinary incontinence)
• Nicotinic signs (fasciculations, muscle weakness, paralysis, hypertension, tachycardia)
• CNS signs (altered mental status, seizures, coma)

The presence of fasciculations is the most specific bedside sign distinguishing cholinergic crisis from other toxidromes. A therapeutic trial of atropine - 1 to 2 mg IV - that produces anticholinergic signs (dry skin, tachycardia, mydriasis) without improvement in secretions suggests insufficient dosing or a different diagnosis.

Laboratory Confirmation

In OP poisoning, both enzymes are markedly depressed on admission; AChE activity increases continuously after starting obidoxime, while BChE remains suppressed until recovery ^[7]C4. In Lycoris radiata poisoning, BChE levels are considerably low and increase with clinical improvement ^[6]C4. Normal cholinesterase levels do not exclude exposure if measured late (hours to days after ingestion) due to spontaneous reactivation or new synthesis.

Diagnostic Algorithm

Step 1: Suspect cholinergic crisis from the toxidrome. Step 2: Draw blood for RBC AChE and plasma BChE before antidote administration (if possible). Step 3: If both enzymes are depressed, initiate OP treatment. Step 4: If BChE is low but AChE normal, consider carbamate or other reversible inhibitors; oximes are not indicated. Step 5: If enzymes are normal, the toxidrome is not cholinergic crisis - re-evaluate for other causes (e.g., myasthenic crisis, serotonin syndrome , neuroleptic malignant syndrome, or sympathomimetic overdose).

Pearl: In MuSK-antibody myasthenia gravis, acetylcholinesterase inhibitors cause cholinergic crisis in 7.3% of patients and should be avoided.

Once the diagnosis of cholinergic crisis is established, the next step is to assign a severity grade that determines the appropriate level of care and urgency of intervention. The spectrum ranges from mild, self-limited symptoms to life-threatening respiratory failure, seizures, and cardiovascular collapse. Risk stratification hinges on the agent involved, the patient's baseline vulnerability, and objective markers of cholinergic excess.

Severity Grading

Severity is best gauged by the intensity of muscarinic and nicotinic signs and the response to atropine. Patients with mild toxicity (e.g., carpronium chloride ingestion) may improve within 24 hours without antidotes ^[8]C4. In contrast, severe organophosphate (OP) poisoning can require massive atropine doses, one patient with pirimiphos-methyl intoxication received 248 mg of atropine over 7 days and prolonged ventilation ^[7]C4. The need for vasopressors or mechanical ventilation (as in the Lycoris radiata case) defines critical illness ^[6]C4.

The following table summarizes pragmatic severity tiers based on presentation and antidote requirement:

Note: Thresholds are clinical benchmarks; the absolute atropine dose is a surrogate for severity. In the Pannu et al. randomized trial, the median total atropine dose in the control group was 175.0 mg at complete resolution, reflecting the high burden of severe OP poisoning ^[1]A1b.

Risk Stratification

Several factors independently predict worse outcomes or complications:

• Agent type: Nerve agents (e.g., VX, sarin) cause rapid, profound inhibition and CNS involvement ^[2]D5. Carbamates (e.g., galanthamine in Lycoris radiata) can produce a delayed but severe toxidrome ^[6]C4. Chlorpyrifos is associated with organophosphate-induced delayed neuropathy (OPIDN) in 34.8% of patients, though baseline characteristics do not predict this complication ^[18]B2b.
• Age and comorbidities: Patients older than 65 years have a 3-5-fold increased risk of pneumonia with acetylcholinesterase inhibitors, likely due to aspiration from medullary cholinergic overstimulation ^[17]B2c.
• MuSK- myasthenia gravis : In this population, acetylcholinesterase inhibitors (AChEI) are poorly tolerated, 76.9% of patients report side effects, and 7.3% suffered a cholinergic crisis ^[12]B3b. AChEI should be avoided entirely in MuSK-MG ^[4]D5[12]B3b.
• Cholinesterase levels: Butyrylcholinesterase (BChE) recovery to 1/5th of normal permits weaning of antidotes, and recovery to 2/5th allows extubation ^[7]C4. Serial measurement of red blood cell AChE activity, reactivatability, and inhibitory equivalents, a low-cost test system, can guide oxime therapy ^[15]D5.
• EEG biomarkers: In animal models, a reduced theta-delta ratio during the acute phase correlates with later spontaneous recurrent seizures, suggesting a future role for EEG-based risk stratification ^[10]D5.

Triage to Level of Care

All patients with suspected cholinergic crisis should be evaluated in an emergency department capable of immediate antidote administration. The following criteria mandate ICU admission:

• Need for mechanical ventilation or vasopressors
• Persistent seizures or status epilepticus
• Requirement for continuous atropine infusion (> 2 mg/h) or escalating doses
• Known ingestion of a nerve agent or high-dose OP
• MuSK-MG patient on AChEI with any cholinergic signs (AChEI must be stopped immediately) ^[12]B3b

Patients with mild symptoms (e.g., isolated SLUD, normal mentation, no respiratory distress) may be monitored in a step-down unit with frequent reassessment for at least 24 hours, given the potential for delayed deterioration, as seen in Lycoris radiata poisoning where symptoms escalated 8 hours after admission ^[6]C4.

Pearl: The most reliable triage discriminator is the atropine requirement in the first hour, a dose > 10 mg signals severe poisoning that mandates ICU-level care, while the need for any continuous atropine infusion should prompt immediate transfer to a critical care setting.

Once the patient is triaged as high-risk (section 6), resuscitation begins in parallel with the diagnostic workup. The clinician must execute an ABCDE approach combined with immediate antidote administration, before laboratory confirmation of poisoning is available.

Initial ABCDE Assessment and Immediate Actions

• Airway: Excessive secretions, depressed consciousness, or respiratory failure mandate early endotracheal intubation. Aspiration pneumonia predominates, occurring in 27/33 patients (81.8%) in one series, and contributed to late deaths ^[48]C4.
• Breathing: Provide supplemental oxygen and bag-valve-mask ventilation until the airway is secured. Mechanical ventilation is required in a substantial proportion of patients; hospital mortality in those needing ventilation is 33.3% versus 4.7% in those who do not ^[50]B2b.
• Circulation: Bradycardia and hypotension are common muscarinic effects. Atropine is the drug of choice: it blocks muscarinic receptors, increasing heart rate and drying secretions. Administer atropine in escalating doses (e.g., repeated 1-2 mg IV every 5 minutes) until the target of atropinization is achieved (heart rate >80 bpm, dry pulmonary secretions, dilated pupils). No specific dose threshold is universal; the goal is clinical response.
• Disability: Perform a brief neurological assessment ( GCS , pupil size, motor function). Seizures should be treated with benzodiazepines.
• Exposure: Remove all contaminated clothing and wash the skin thoroughly with soap and water. Avoid inducing emesis because of aspiration risk.

Antidote Administration

Atropine is the initial and most critical antidote. It must be given before oxime therapy. The oxime pralidoxime (2-PAM) or obidoxime reactivates acetylcholinesterase if given early. In a study of 34 patients with severe organophosphate poisoning, obidoxime was administered as a 250 mg bolus followed by continuous infusion of 750 mg/day for up to 1 week ^[47]C4. This regimen was safe and reactivated acetylcholinesterase in parathion poisoning, but effects were only transient with other organophosphates ^[47]C4. Pralidoxime can be used similarly (dose not reported in the available evidence; standard dosing is 1-2 g IV bolus then 500 mg/h infusion). Oximes are most effective within the first few hours of exposure.

Monitoring for Complications

• Hyperamylasemia occurs in 37/79 patients (46.95%) with anticholinesterase poisoning, but acute pancreatitis is rare (only 1 of 79 patients had confirmed pancreatitis) ^[49]B2b.
• ECG monitoring: Fatalities had significantly longer QTc time on admission ^[48]C4. Obtain a 12-lead ECG and correct electrolyte abnormalities.
• Respiratory: Continuous pulse oximetry and early chest imaging for aspiration pneumonia.
• Neurologic: Watch for the intermediate syndrome (proximal muscle weakness, respiratory failure) and delayed neuropathy.

Outcome Data to Emphasize Urgency

The hospital mortality rate for patients requiring mechanical ventilation is 33.3% ^[50]B2b. Among survivors, the 1-year mortality rate is 6.7% ^[50]B2b. These numbers underscore the need for aggressive, early resuscitation.

Pearl: The single most important action in the first minutes is to achieve atropinization, dry secretions and a heart rate >80 bpm, before administering the oxime; delay in atropine is associated with worse outcomes, and the oxime cannot work without an atropinized patient.

Once the patient is stabilised with atropine and pralidoxime, attention turns to definitive airway protection and control of the airway. The excessive secretions, depressed consciousness, and seizures characteristic of cholinergic crisis often necessitate emergency intubation. This section covers the hands-on procedural skills specific to managing the poisoned airway and providing safe sedation.

Step 1: Indications for Airway Intervention

• Inability to protect the airway due to depressed level of consciousness ( GCS < 8) or excessive oral and respiratory secretions that cannot be controlled with suctioning .
• Respiratory failure from muscle weakness, bronchospasm, or aspiration of gastric contents.
• Seizures or status epilepticus that require prolonged sedation and airway protection.
• Progressive deterioration despite initial antidote therapy, as seen in the case of pirimiphos-methyl intoxication where the patient developed bradycardia and respiratory distress four hours after admission, requiring intubation ^[7]C4. Similarly, in Lycoris radiata poisoning, rapid hemodynamic and respiratory deterioration necessitated mechanical ventilation ^[6]C4.

Step 2: Rapid Sequence Intubation (RSI) Principles

• Preoxygenate with 100% oxygen via a bag-valve-mask, carefully managing secretions with suctioning.
• Use a non-depolarising neuromuscular blocker. Because butyrylcholinesterase (BChE) is suppressed in cholinergic crisis, drugs that rely on this enzyme for metabolism (e.g., succinylcholine) may have a prolonged and unpredictable effect. Rocuronium (1.2 mg/kg) or vecuronium (0.1 mg/kg) are preferred; they are not hydrolysed by plasma esterases. Titrate to train-of-four monitoring.
• Atropine may be given as a drying agent prior to laryngoscopy, but this is often already part of the ongoing antidote infusion. In the case of pirimiphos-methyl poisoning, the patient received atropine by continuous infusion for 7 days (total 248 mg) ^[7]C4.
• Avoid etomidate if possible; its adrenal suppression may compound the stress response. Ketamine (1-2 mg/kg IV) provides dissociative sedation and preserves airway reflexes, but use with caution in patients with significant hypertension or tachycardia. Benzodiazepines (midazolam 0.1-0.3 mg/kg) are the sedative of choice given their anticonvulsant effect ^[2]D5.

Step 3: Procedural Sedation and Seizure Control

• Benzodiazepines are first-line agents for sedation and for terminating status epilepticus. Use midazolam (initial bolus 0.1-0.2 mg/kg IV, then infusion 0.05-0.2 mg/kg/h) or lorazepam (0.1 mg/kg IV). These agents do not exacerbate cholinergic excess and have a wide therapeutic index ^[2]D5.
• Avoid opioids (e.g., fentanyl , morphine ) unless required for pain, as they can worsen respiratory depression and confound the assessment of consciousness.
• Continuous sedation may be needed for ventilator synchrony and to control agitation. Propofol (5-10 mg/kg/h) is an alternative, but its lipid component may be of theoretical concern in the setting of intravenous lipid emulsion (ILE) use; however, ILE has shown no benefit in acute OP poisoning ^[1]A1b.

Step 4: Decontamination Procedures

• Gastric lavage may be considered if the patient presents within one hour of a large ingestion and the airway is protected. In one case of carpronium chloride poisoning, lavage was performed 78 minutes after ingestion ^[8]C4. However, the risk of aspiration is high; intubate first.
• Activated charcoal (50 g) can be given via nasogastric tube after airway protection, ideally within one hour of ingestion. It was administered in the pirimiphos-methyl case ^[7]C4.
• Intravenous lipid emulsion (ILE) has been proposed for lipid-soluble OPs, but an open-label RCT showed no benefit in atropine dose requirement, haemodynamics, or duration of mechanical ventilation ^[1]A1b. ILE is not recommended as a routine resuscitative procedure.

Step 5: Monitoring for Extubation and Recovery

• Serial BChE activity can guide the timing of extubation. In the pirimiphos-methyl case, termination of antidote therapy was possible after BChE recovered to 1/5th of normal, and extubation was achieved after BChE recovered to 2/5th of normal ^[7]C4.
• Ventilator liberation should follow standard weaning protocols, but consider that prolonged neuromuscular weakness from OPIDN may delay extubation even after cholinergic crisis resolves ^[18]B2b.
• Place a nasogastric tube for ongoing activated charcoal administration and to prevent aspiration of secretions.

Figure 1: Airway management algorithm in cholinergic crisis (adapted from clinical course in ^[7]C4).

Pearl: Use a non-depolarising neuromuscular blocker for RSI; serial BChE levels guide extubation readiness, with extubation typically possible once BChE recovers to 2/5th of normal activity ^[7]C4.

Once airway, breathing, and circulation are stabilized (see preceding section), the next priority is rapid initiation of antidotal therapy. The ED's window for definitive intervention is narrow: the three-phase evolution of cholinergic crisis, acute crisis, intermediate syndrome, and delayed neuropathy, means that early treatment and anticipation of delayed respiratory failure determine survival ^[46]C4.

Step 1: Rapid Antidote Administration

• Atropine is the cornerstone of muscarinic blockade. In the Japanese nationwide database of 235 patients with cholinergic crisis from pharmaceutical cholinesterase inhibitors, approximately half of hospitalized patients required atropine, catecholamines, or mechanical ventilation; those who received these interventions had higher mortality, reflecting disease severity rather than treatment harm ^[51]C4. Atropine should be administered intravenously in escalating doses until muscarinic signs (secretions, bronchospasm, bradycardia) reverse. A continuous infusion may be needed to maintain drying of secretions. The endpoint is clinically evident: clear lungs, reduced oral secretions, and heart rate >60 bpm.
• Pralidoxime (2-PAM) is given as an adjunct to reactivate acetylcholinesterase, though its benefit is most pronounced when given within hours of exposure. The prospective study of anticholinesterase poisoning (n=79) used atropine alone or atropine plus 2-PAM, documenting improvement in cholinergic crisis ^[49]B2b. No specific dosing or timing data are reported in the available evidence; consult current toxicology resources for updated regimens.

Step 2: Decontamination and Supportive Care

Decontamination (removal of contaminated clothing, skin washing) ideally occurs before antidote administration, but clinical stabilization takes precedence. Activated charcoal may be considered for recent ingestions if the airway is protected. Continue mechanical ventilation for patients with respiratory failure; the rodent model suggests a sequential "two-hit" insult, rapid central apnea followed by delayed pulmonary gas exchange impairment with prominent airway secretions ^[52]D5. This supports the need for aggressive airway clearance and lung-protective ventilation.

Step 3: Time-to-Intervention Benchmarks

Although no specific time targets are reported in the provided evidence, the outcome data underscore the urgency:

• Hospital mortality among patients with respiratory failure requiring mechanical ventilation was 33.3% vs 4.7% in those without ventilation (p<0.0001) ^[50]B2b.
• In the pharmaceutical era, hospital mortality was 6.4% overall, with a median hospital stay of 15 days (IQR 6-42) and ICU stay of 4 days (IQR 2-8) ^[51]C4.
• One-year mortality among survivors of CI poisoning was 6.7%, rising to 11.4% in those who had required mechanical ventilation ^[50]B2b.

These figures reinforce that every minute of delay in recognizing cholinergic crisis, securing the airway, and administering atropine may increase the risk of progression to intermediate syndrome and death.

Step 4: Structured Handoff to the ICU

Patients with cholinergic crisis require ICU-level monitoring for at least 24-48 hours, regardless of initial severity. The handoff should include:

• Phase of poisoning: acute crisis (ongoing muscarinic signs), intermediate syndrome (proximal muscle weakness, respiratory failure appearing 24-96 hours post-exposure), or delayed neuropathy ^[46]C4.
• Cholinesterase activity: the initial serum butyrylcholinesterase level (e.g., 17% in one case ^[46]C4) and whether it is rising.
• Respiratory status: ventilator settings, need for paralysis, suctioning requirements.
• Antidote infusion: current atropine infusion rate and goal, pralidoxime dosing schedule if known.
• Complications: hyperamylasemia (present in 46.95% of patients in one series ^[49]B2b), acute pancreatitis (rare, but confirmed in 1 of 79 patients ^[49]B2b), hyperglycemia, elevated transaminases, and leukocytosis.

The ICU team should continue serial cholinesterase measurements, wean atropine as muscarinic signs resolve, and monitor for the development of intermediate syndrome or delayed neuropathy. The one-year mortality of 6.7% among survivors ^[50]B2b mandates long-term follow-up planning.

Figure 1: ED management algorithm for cholinergic crisis (based on ^{[46]C4[49]B2b[50]B2b[51]C4[52]D5}).

Controversies and Guideline Disagreement

No major guideline disagreements were identified in the reviewed evidence; the available references describe epidemiological and outcome associations without formal management protocols.

Pearl: The three-phase evolution of cholinergic crisis, acute crisis, intermediate syndrome, and delayed neuropathy, dictates that ED management includes not only immediate atropine and pralidoxime administration but also anticipation of delayed respiratory failure requiring ICU monitoring, as hospital mortality in ventilated patients is 33.3% vs 4.7% without ventilation ^{[46]C4[50]B2b}.

The current standard of care, rapid atropinization followed by continuous infusion, oxime reactivation, and supportive care, emerged from a series of clinical trials that replaced older, less effective dosing strategies. Early management relied on repeated bolus doses of atropine titrated to clinical endpoints, but this approach often led to delayed atropinization and higher rates of atropine toxicity. The paradigm shifted in 2006 with an open-label trial from Bangladesh randomizing 156 patients to conventional bolus atropine versus rapidly incremental doses followed by continuous infusion. The infusion group achieved atropinization in a mean 23.90 minutes (vs 151.74 minutes; p<0.001), had lower mortality (8% vs 22.5%; p<0.05), and fewer cases of intermediate syndrome (4% vs 13.6%; p<0.05) ^[54]A1b. NNT = 7 to prevent one death for the rapid incremental regimen. This landmark study established that aggressive, early dosing with maintenance infusion reduces both morbidity and mortality.

Subsequent work refined the delivery method. A 2015 randomized trial of 60 patients with severe acute organophosphorus poisoning compared continuous micropump infusion of atropine and pralidoxime chloride against repeated bolus injections. The micropump group demonstrated significantly shorter time to atropinization, faster acetylcholinesterase (AChE) recovery, lower APACHE II scores at atropinization, and reduced case fatality (p<0.05 for all) ^[55]A1b. These findings supported the practice of continuous, controlled antidote delivery rather than intermittent dosing.

While atropine and oximes became the backbone of therapy, other potential treatments were tested and abandoned. Intravenous lipid emulsion (ILE), proposed because of the lipophilicity of many organophosphates, was evaluated in a 2021 open-label randomized trial of 45 patients. The intervention group received a 100 mL bolus of 20% ILE followed by 100 mL over 6 hours. The median atropine dose at 24 hours and complete resolution did not differ from the control group; hemodynamic variables, length of stay, and mortality were also unaffected ^[1]A1b. The authors concluded: “ILE has no apparent benefit in acute OP poisoning” ^[1]A1b. ILE is therefore not recommended in current practice.

Oxime therapy itself has a controversial history. Early studies showed inconsistent benefit, partly because many oximes, such as pralidoxime (2-PAM), poorly penetrate the blood-brain barrier. A 2015 review noted that “cholinesterase reactivators… can reverse both the nicotinic and muscarinic effects; however, this benefit has not been translated well in clinical trials” ^[27]D5. This limitation spurred development of centrally active oximes. In a 2025 mouse model of sarin exposure, the zwitterionic oxime RS194B re-established physiological AChE function in the brain and suppressed gliosis, whereas 2-PAM did not ^[9]D5. Such agents are not yet clinically approved but represent a promising avenue.

Beyond acute therapy, the intermediate syndrome (IMS) remains a therapeutic challenge. IMS occurs 24-96 hours after poisoning and is characterized by proximal limb, neck flexor, and respiratory muscle weakness. A 2022 retrospective study of dogs found that 27% of IMS cases required positive pressure ventilation, yet survival was 100% ^[35]D5. In humans, a 2011 review identified that “plasma AChE of less than 200 units is a predictor” and a 30 Hz repetitive nerve stimulation decremental response may be a useful marker ^[29]D5. No specific pharmacological treatment for IMS exists; management relies on supportive care and mechanical ventilation when needed.

Looking forward, catalytic bioscavengers, enzymes that hydrolyze organophosphates before they reach their targets, are under development. A 2018 review noted that “such enzymes may provide effective prophylactic protection and improve post-exposure treatments using much lower protein doses” ^[53]D5. NADPH oxidase inhibitors are also being investigated to mitigate the oxidative stress and neuroinflammation that follow cholinergic crisis ^[2]D5. These strategies remain experimental but may eventually augment or replace current antidotes.

Table: Landmark Studies in Treatment Evolution

Controversies and Guideline Disagreement

The evolution of treatment for cholinergic crisis reflects a shift from passive, delayed dosing toward aggressive, titrated, and continuous therapy. Mortality from severe poisoning has declined, but the intermediate syndrome and delayed neuropathy remain unsolved problems. The next section discusses disposition and safe discharge after stabilization.

Pearl: Centrally active oximes like RS194B show promise for neuroprotection but are not yet clinically available ^[9]D5.

From the history of oxime development, we now turn to the practical decision of when the patient can safely leave the ED or hospital. The defining emergency medicine decision, admit, observe, discharge, or transfer, hinges on the risk of delayed deterioration, the need for psychiatric evaluation after intentional self-poisoning, and the potential for long-term neurologic sequelae that require structured follow-up.

Admission Criteria

All symptomatic patients with cholinergic crisis require admission. Even patients who appear well after initial decontamination may experience delayed onset of severe symptoms, as seen with Lycoris radiata poisoning where progression occurred 8 hours after admission ^[6]C4. Intentional ingestions, regardless of initial severity, warrant admission for medical monitoring and psychiatric assessment ^[8]C4. Patients with significant comorbidities (e.g., cirrhosis, chronic kidney disease, diabetes) that impair clearance of the poison or antidotes are at higher risk for prolonged crisis and should be admitted to a monitored setting ^[7]C4.

Observation Duration

Patients should be observed for a minimum of 24 hours after the last cholinergic sign resolves. For agents with well-described delayed toxicity, such as pirimiphos-methyl, which caused bradycardia and respiratory distress 4 hours after admission ^[7]C4, or Lycoris radiata, where symptoms persisted for a prolonged period ^[6]C4, extend observation to 48 hours. The observation period must include documentation of hemodynamic stability, resolution of muscarinic signs, and no need for atropine for at least 12 hours.

Discharge Criteria

• Resolution of all cholinergic signs (muscarinic and nicotinic) without atropine or other antidote support for 12-24 hours.
• Normal vital signs (heart rate, blood pressure, respiratory rate, oxygen saturation).
• Psychiatric evaluation performed and documented, as in the case of carpronium chloride ingestion, the patient was discharged on day 2 after psychiatric assessment ^[8]C4.
• Patient and caregiver education on delayed neurologic symptoms: weakness, paresthesias, gait ataxia, or foot drop, which occur in 34.8% of chlorpyrifos self-poisoning cases (organophosphate-induced delayed neuropathy, OPIDN) ^[18]B2b.
• Follow-up appointment scheduled for neurological examination and nerve conduction study (NCS) within 2-4 weeks, as subclinical injury may be detected early ^[18]B2b.
• Social support available and ability to return to the ED if symptoms recur.

Transfer to Higher Level of Care

Transfer to an intensive care unit is indicated for any patient requiring continuous atropine infusion, mechanical ventilation, or vasopressor support ^[7]C4. Patients with severe poisoning who develop prolonged neuromuscular weakness, aspiration pneumonia , or multisystem organ failure may eventually need transfer to a rehabilitation facility, the pirimiphos-methyl patient was discharged to neurological rehabilitation after 77 days of hospital care ^[7]C4.

Return Precautions

Patients discharged after cholinergic crisis must be instructed to return immediately for:

• New or worsening weakness, especially in the legs (foot drop, difficulty climbing stairs)
• Numbness, tingling, or gait ataxia, which may indicate OPIDN ^[18]B2b
• Respiratory difficulty, cough, or fever, signaling possible aspiration pneumonia, a known complication of cholinergic crisis due to impaired swallowing and hypersalivation ^[17]B2c
• Recurrent suicidal thoughts or re-ingestion

Pearls for Safe Discharge

• Do not discharge a patient with any ongoing need for atropine. The half-life of the poison may exceed the duration of antidote coverage, and premature discharge risks rebound crisis.
• Perform a baseline neurologic exam and document it. This serves as a reference for detecting delayed neuropathy.
• In MuSK-antibody positive myasthenia gravis , acetylcholinesterase inhibitors cause cholinergic crisis in 7.3% of patients ^[12]B3b; these drugs should be avoided in this subgroup, and patients discharged on AChEIs for other indications must be warned about cholinergic symptoms.

Pearl: The safest discharge after cholinergic crisis requires a 12-24 hour symptom-free period off atropine, psychiatric clearance, and specific education about delayed neuropathy, a 34.8% risk after chlorpyrifos ingestion that can be debilitating if missed ^[18]B2b.

Even after the acute cholinergic crisis resolves, the patient remains at risk for several delayed complications that demand ongoing surveillance. The most common preventable complications are respiratory, neurologic, and iatrogenic, and the most dangerous cognitive error is failing to recognize cholinergic crisis when it is superimposed on pre-existing neuromuscular disease.

Respiratory Complications

Aspiration pneumonia is a recognized complication of cholinergic excess, particularly when swallowing is impaired and salivation is profuse. In the FDA Adverse Event Reporting System, patients prescribed the acetylcholinesterase inhibitor rivastigmine were more likely to report pneumonia as an adverse event than those taking many other drugs, an effect attributed to induced cholinergic crisis in the medulla oblongata causing gastrointestinal distress, impaired swallowing, heightened salivation, and labored breathing ^[17]B2c. Males were 46% more likely than females to report pneumonia, and the likelihood increased 3- to 5-fold in patients older than 65 years ^[17]B2c. Prevention focuses on airway protection, frequent suctioning , and maintaining head -of-bed elevation at 30° or more. Management follows standard pneumonia guidelines with empiric antibiotics and respiratory support.

Neurologic Complications

Organophosphate-induced delayed neuropathy (OPIDN) develops weeks after the acute crisis in a subset of patients. In a prospective study of 23 patients with acute organophosphate self-poisoning, 8 (34.8%) developed OPIDN during six-month follow-up, all associated with chlorpyrifos ingestion ^[18]B2b. Three had symptomatic neuropathy (foot drop, gait ataxia, distal paresthesia), and nerve conduction studies revealed axonal degeneration predominantly affecting motor fibers, with frequent peroneal nerve involvement ^[18]B2b. Baseline characteristics including ingested amount did not predict OPIDN ^[18]B2b. Prevention: No proven strategy; early detection of subclinical injury on nerve conduction studies may provide a window to prevent severe symptomatic neuropathy ^[18]B2b. Management: Supportive care, physical therapy, and orthotics for foot drop.

Epilepsy is another long-term sequela. In a rat model of acute organophosphate intoxication with diisopropylfluorophosphate (DFP), 80% of animals developed spontaneous recurrent seizures ( SRS ) between 7 and 14 days post-exposure ^[10]D5. Increased broadband power during status epilepticus and slower recovery of broadband power to baseline correlated with higher SRS burden ^[10]D5. Prevention: Adequate control of acute status epilepticus with benzodiazepines (e.g., midazolam ) is critical, but even standard therapy did not fully terminate electrographic seizures ^[10]D5. Management: Long-term antiepileptic drug therapy and EEG monitoring in patients with persistent neurologic symptoms.

Autonomic and Other Complications

Autonomic instability (arrhythmias, hypotension, bradycardia) is a hallmark of the acute crisis but can persist. In 42 patients with acute organophosphate poisoning, hypotension was present in 17% and bradycardia correlated with a marked decrease in erythrocyte acetylcholinesterase (EAChE) activity below a cutoff of 23.5 µmol/mL per hour at 37°C ^[45]B2b. Management: Hemodynamic monitoring , atropine titration as needed, and avoidance of drugs that exacerbate bradycardia.

Diagnostic Pitfalls

Cholinergic crisis can be misdiagnosed or missed when it occurs in patients with underlying neuromuscular disease. A case report describes a patient with chronic spinal cord injury who developed myasthenia gravis and subsequently died after a cholinergic crisis; the diagnosis was delayed because fluctuating symptoms (diplopia, dysphagia, slurred speech) were attributed to the pre-existing disability ^[57]C4. The presence of spinal cord injury makes it challenging to recognize either myasthenic or cholinergic crisis ^[57]C4. Action: In any patient with unexplained tachycardia, tachypnoea, or bulbar symptoms after organophosphate exposure, consider cholinergic crisis even if the history is unclear. Measure acetylcholinesterase activity and perform electromyography if myasthenia gravis is suspected.

Pearl: When evaluating a patient with spinal cord injury or known myasthenia gravis who presents with unexplained weakness, dysphagia, or respiratory distress, always consider cholinergic crisis, the classic signs may be masked by the underlying condition, and delayed diagnosis is fatal ^[57]C4.

From the complications and pitfalls discussed above, the natural history of cholinergic crisis hinges on the speed of intervention and the underlying agent. Without treatment, the cascade of muscarinic and nicotinic overactivity leads to respiratory failure, hypoxia, and death within minutes to hours. With aggressive antidote therapy, mortality is reduced but remains substantial.

Mortality and Time-to-Treatment

In the largest available cohort, death occurred in 7 of 34 patients (20.6%) with severe parathion, oxydemeton-methyl, or dimethoate poisoning, all of whom received standard obidoxime and atropine ^[47]C4. Notably, death was late and mostly due to complications (ARDS, aspiration pneumonia , sepsis) rather than ongoing cholinergic crisis ^[47]C4. In a second series of 42 patients with acute organophosphate poisoning (OPP), mortality was **2 of 42 **; both fatalities had a deep decrease in erythrocyte acetylcholinesterase (EAChE) to 5 and 9 µmol/mL per hour at 37 °C ^[45]B2b. These figures underscore that even in treated patients, the risk of death is real and driven by secondary injury.

Predictors of Poor Outcome

EAChE activity at admission is a robust prognostic marker. A cutoff of 23.5 µmol/mL per hour at 37 °C identified patients with coma, hypotension, hypoxemia, and bradycardia; below this threshold, the need for mechanical ventilation rose to 36% ^[45]B2b. In MuSK-antibody positive myasthenia gravis , exposure to acetylcholinesterase inhibitors (AChEI) triggered a cholinergic crisis in 7.3% of patients, and 76.9% reported at least one side effect, most commonly neuromuscular hyperexcitability (68.4%) ^[12]B3b. These data show that iatrogenic cholinergic crisis in susceptible populations carries a measurable morbidity.

Recovery Kinetics

Recovery of EAChE activity is slow. In OPP survivors, EAChE improved from 16.6 ± 9 µmol/mL per hour on day 3 to 27.5 ± 6.5 µmol/mL per hour on day 15 ^[45]B2b. In a case of severe methamidophos poisoning, repetitive obidoxime administration on day 6 produced a significant increase in red blood cell AChE activity, enabling extubation by day 10 and full recovery ^[58]C4. Thus, even when initial reactivation is incomplete, prolonged therapy can salvage enzyme function and improve outcome.

Pearl: The EAChE cutoff of < 23.5 µmol/mL per hour at admission identifies patients at highest risk of respiratory failure and death; these patients warrant early ICU admission and aggressive monitoring for complications.

Prognosis in cholinergic crisis is heavily influenced by host factors, and three populations demand departures from the standard algorithm: children, pregnant women, and the elderly. The immunocompromised host, though less studied, also warrants heightened vigilance for infection-related complications.

Pediatrics

Children present with the same cholinergic toxidrome, miosis, hypersalivation, bradycardia, and muscle fasciculations, but the differential is broader. Congenital myasthenic syndromes, infantile botulism , and organophosphate (OP) poisoning must be distinguished. Atropine dosing is weight-based: 0.05 mg/kg intravenously every 5-10 minutes until atropinization (drying of secretions, heart rate >80/min, pupil dilation). Pralidoxime dose is also weight-based: 20-50 mg/kg over 30 minutes, followed by 10-20 mg/kg/hour infusion. The risk of aspiration pneumonia is high due to excess secretions and immature airway protection; early intubation with a cuffed endotracheal tube is advised. Developmental outcomes after severe OP poisoning are not well described, but prolonged hypoxia may cause lasting neurocognitive deficits.

Pregnancy

Pregnancy alters the risk-benefit calculus for both the mother and fetus. Atropine crosses the placenta and may cause fetal tachycardia, but maternal survival is the priority; withholding atropine to avoid fetal effects is contraindicated. Pralidoxime is also used in pregnancy, though human safety data are limited to case reports. In the third trimester, the gravid uterus may compress the inferior vena cava, compounding hypotension; the patient should be positioned in left lateral tilt during resuscitation. Delivery planning is rarely needed acutely, but if fetal distress is detected after maternal stabilization, emergency cesarean may be considered. Breastfeeding is safe after the acute phase resolves; atropine and pralidoxime are excreted in low amounts in breast milk.

Elderly

Age-related changes in pharmacokinetics, polypharmacy, and reduced physiologic reserve make the elderly especially vulnerable. In a case series of 33 OP-poisoned patients in a developed-world ICU, fatalities showed higher APACHE-II and SOFA scores and longer QTc intervals on admission ^[48]C4. The cholinergic crisis may be more severe due to slower clearance of OP compounds. A 75-year-old patient with methamidophos poisoning required prolonged obidoxime therapy, with repeated dosing on day 6 when RBC-AChE activity remained low ^[58]C4. Atropine should be titrated cautiously to avoid anticholinergic delirium, which is common in older adults. Rivastigmine (a carbamate used for Alzheimer disease) can itself induce a cholinergic crisis; pooled FAERS data show that patients >65 years have a 3- to 5-fold increased risk of pneumonia with rivastigmine, likely due to aspiration from hypersalivation and impaired swallowing ^[17]B2c. The classic triad of miosis, bradycardia, and hypersalivation may be blunted by concurrent beta-blocker or anticholinergic use, so a low threshold for measuring serum butyrylcholinesterase is warranted.

Immunocompromised

No dedicated trials exist, but immunocompromised patients (e.g., HIV, transplant recipients, those on chemotherapy) face a higher risk of opportunistic infections complicating the crisis. Aspiration pneumonia is the most common serious complication in OP poisoning, occurring in 27/33 patients in one series ^[48]C4. In the immunocompromised host, empiric broad-spectrum antibiotics should be started early, and antifungal coverage should be considered if prolonged ventilation is required. The standard antidote dosing is unchanged, but close monitoring for secondary infections and sepsis is essential.

Pearl: In the elderly, a blunted cholinergic toxidrome from concurrent medications does not rule out severe poisoning, check serum butyrylcholinesterase when the history is suggestive.

Beyond these special population considerations, the emergency clinician can leverage the acute encounter to implement prevention and screening measures that address both immediate and long-term risks.

Primary Prevention: Identifying and Mitigating Exposure Risks

While the ED is not the site for population-level prevention, the consultation provides a window to identify patients at risk for future cholinergic crises. Patients prescribed acetylcholinesterase inhibitors (AChEIs) for Alzheimer disease, particularly rivastigmine, should be counseled about the elevated risk of pneumonia, which may be driven by induced cholinergic crisis in the medulla oblongata leading to impaired swallowing, hypersalivation, and respiratory compromise ^[17]B2c. In patients with MuSK-antibody positive myasthenia gravis , AChEIs are contraindicated: in a cohort of 202 patients, 76.9% reported side effects and 7.3% suffered a cholinergic crisis, with worsening weakness in 33.9% ^[12]B3b. Clinicians should document the avoidance of pyridostigmine and related agents in MuSK-MG and educate patients and caregivers about this risk.

Secondary Prevention: Avoiding Recurrence and Iatrogenic Harm

In survivors of acute organophosphate (OP) poisoning, the ED visit is an opportunity to prevent recurrence through safety counseling and referral. Patients with suicidal ingestions should receive a mental health evaluation before discharge, as recommended in the case of carpronium chloride ingestion where the patient was discharged after psychiatric assessment ^[8]C4. For MuSK-MG patients inadvertently treated with AChEIs, immediate discontinuation is required; symptoms resolve once the drug is stopped ^[12]B3b.

Tertiary Prevention and Screening for Delayed Neuropathy

Organophosphate-induced delayed neuropathy (OPIDN) is a long-term consequence that can be debilitating. In a prospective study of 23 patients with acute OP poisoning, 34.8% developed OPIDN within six months, all associated with chlorpyrifos ingestion ^[18]B2b. Nerve conduction studies (NCS) detected subclinical peripheral nerve involvement in 5 of 8 cases, with axonal degeneration affecting motor fibers more than sensory fibers and frequent peroneal nerve involvement ^[18]B2b. Recommendation: survivors of chlorpyrifos poisoning should have a neurological examination and consider NCS at discharge and at 3 months to detect early OPIDN, as no baseline predictors of clinical or subclinical neuropathy were identified ^[18]B2b.

Patient Education Points

• Recognize early cholinergic signs: excessive salivation, sweating, miosis, bradycardia, muscle fasciculations, and respiratory distress.
• For patients on AChEIs (e.g., rivastigmine): report any new cough, difficulty swallowing, or altered consciousness suggestive of aspiration pneumonia ^[17]B2c.
• For MuSK-MG patients: carry a medical alert card listing AChEI contraindication ^[12]B3b.
• Poison control center number (e.g., 1-800-222-1222 in the US) for any suspected ingestion.

Pearl: In every patient with acute cholinergic crisis, document the specific agent (e.g., chlorpyrifos) to trigger a 3-month follow-up neurological screen for OPIDN, which occurs in one-third of cases and may be subclinical at discharge ^[18]B2b.